CryoLife Announces Fiscal Year 2000 Revenues and Earnings, Release Date and Teleconference Call Details

January 24, 2001 at 8:38 AM EST

ATLANTA, Jan. 24 /PRNewswire/ -- CryoLife, Inc. (NYSE: CRY), the leader in the development and commercialization of tissue-engineered heart valves, vascular grafts and surgical adhesives, announced today that year end and fourth quarter revenues and earnings will be released on January 31, 2001.

The year end financial results are being released ahead of the scheduled release date of February 13, 2001, in conjunction with CryoLife management's presentation at the U.S. Bancorp Piper Jaffray Health Care Conference scheduled for Wednesday, January 31, 2001 at the Pierre Hotel in New York. The Company also announced that following the release of financial results, a teleconference will be held promptly at 8:30 a.m. Eastern Time January 31, 2001 hosted by Steven G. Anderson, CryoLife President and Chief Executive Officer.

Individuals interested in listening to the live teleconference may do so by calling 973-633-1010 a few minutes prior to 8:30 a.m. on January 31, 2001. No identification number is required. Those interested in listening to a replay of the teleconference may do so by calling (toll free) 888-689-6808 or 402-220-9943. The replay will be available January 31 through February 6, 2001.

Founded in 1984, CryoLife, Inc., is the leader in the development and commercialization of implantable living human tissues for use in cardiovascular, vascular and orthopaedic surgeries throughout the United States and Canada. The Company's BioGlue(R) surgical adhesive is approved as an adjunct for acute thoracic aortic dissections under HDE regulations in the United States and is CE marked in the European Union and approved in Canada for use in vascular and pulmonary sealing and repair. The Company also manufactures the SynerGraft(R) heart valve, the world's first tissue- engineered heart valve replacement, and the CryoLife-O'Brien(R) and CryoLife- Ross(R) stentless porcine heart valves, which are CE marked for distribution within the European Community. The Company's SynerGraft processed human heart valves and vascular grafts that are distributed in the U.S. are marketed under the trade names of CryoValve(R)-SG and CryoVein(R)-SG, respectively.

For additional information about the company, visit CryoLife's web site: http://www.cryolife.com . SOURCE CryoLife, Inc.

CONTACT: D. Ashley Lee, Vice President, Chief Financial Officer of CryoLife, Inc., 800-438-8285/